Skip to content

ALPHAROSE THERAPEUTICS

Cures made in days,
not decades.

AlphaRose Therapeutics is building the world's first scalable platform for ultra-rare genetic medicines — starting with the diseases no one else will touch.

Looking for RareLabs?
|| ABOUT { 2 }

THE CRISIS NO ONE TALKS ABOUT

More than 200 million children worldwide are living with rare genetic diseases.

The vast majority — 95% — have zero approved treatments. Not because the science doesn't exist. Because the business model doesn't work.

Traditional drug development was built for blockbusters: big margins, long timelines. If your disease affects fewer than 500 people, you don't get a drug. You get a shrug.

That's not a scientific failure. It's a systems failure. And we're here to fix it.

200
95%
Million children
Untreated
Child living with rare disease
|| STARTED { 3 }

WHY IT STARTED

A father. A daughter. A broken system.

AlphaRose has a simple premise. When Casey McPherson's daughter, Rose, was diagnosed with HNRNPH2-related neurogenetic disease with no treatment and no roadmap — he was told there was nothing to be done.

He refused to accept that.

Casey assembled a team of world-class scientists, built a nonprofit (To Cure A Rose Foundation) and created the first proof-of-concept treatment for Rose's disease in under a year. Not in a decade. Not with hundreds of millions of dollars. In months, with a small team and a profound urgency.

That experience revealed a hard truth: the science is here. Most of these children already today exist. What doesn't exist are the systems, the business model, and the regulatory pathways to deliver it at scale.

AlphaRose Therapeutics was built to change that.

|| WHAT WE BUILT { 4 }

A platform that turns genetic diagnoses into treatments.

Argus

AI-driven target identification engine. Integrates public and proprietary gene datasets with machine learning to triage viable antisense targets. We've already screened over 300 monogenic CNS diseases and identified which ones are amenable to our platform.

MetaMorph

AI sequence design engine. Computationally predicts and optimizes ASO sequences for on-target efficacy, off-target safety, and toxicity profiles — replacing months of wet-lab screening with hours of computational design.

abcDNA

Proprietary backbone chemistry acquired from Alpha Anomeric SA (France). Eliminates sulfur linkages while preserving the phosphate structure required for gene silencing. The result: reduced immune activation, fewer off-target effects, and a cleaner safety profile than conventional phosphorothioate chemistry.

SOT Caller

Epigenetic sense oligonucleotide platform. A first-of-its-kind "sense" technology that recruits endogenous transcription factors to precisely upregulate or downregulate gene expression — opening the door to durable treatments beyond traditional antisense knockdown.

|| THAT SCALES { 5 }
Researcher in lab

THE MODALITY THAT SCALES

Antisense oligonucleotides are the most deployable genetic medicine on the planet.

Gene therapies cost $1.5M+ per dose. They require viral vectors, complex manufacturing, and often can only be administered once. ASOs are different.

ASOs are symbolically reprogrammable, rationally designed, and chronically administered. They've already been approved by the FDA for multiple individualized diseases. Manufacturing costs are a fraction of gene therapy. And because they can be given repeatedly, they generate sustainable revenue per patient — not a one-time payment.

For ultra-rare diseases affecting 50 to 500 patients, ASOs are the only genetic modality where the economics actually work. That's not an opinion. That's math.

AlphaRose isn't betting on ASOs because they're trendy. We're betting on them because they're the only technology that can treat an individual child's disease and still build a viable business around it.

|| 5 PROGRAMS { 6 }

PROGRAMS IN MOTION

From computation to clinic.

  • Rosiphersen — HNRNPH2 (Bain Syndrome)

    Lead asset · IND-Enabling

    The first full application of the AlphaRose platform. Rosiphersen silences the two gain-of-function mutations in HNRNPH2 in vitro and in vivo non-DLP bioassays consistently and modulates splicing efficiently. Demonstrates simultaneous HNRNPH2 reduction and HNRNPH1 upregulation in human neurons. IND-enabling studies planned. Target clinical trials with sub-$30M total development cost in 2–4 years.

  • ASO for Adrenoleukodystrophy — ABCD1

    Preclinical

    Lead candidates designed and computationally screened.

  • SOT Caller for CDKL5 Deficiency — via CDKL2 upregulation

    Preclinical

    Lead candidates designed and computationally screened.

  • SOT Caller for Prion Disease — PRNP

    Preclinical

    Lead candidates designed and computationally screened.

  • ASO for VWD Type 2b — VWF

    Preclinical

    Lead candidates designed and computationally screened.

DNA visualisation
Built to scale
|| MARKET { 7 }

This isn't charity. It's a new category of biotech.

Ultra-rare diseases aren't a niche — they're an untapped market. With orphan drug designation, 7 years of U.S. market exclusivity, 10 years in the EU, and the FDA's Pediatric Review Voucher (worth $75–$100M alone), the regulatory incentives are enormous.

Our lead program, Rosiphersen, is projected at $200–$600K per patient per year, with each patient generating an estimated $3.5M+ in lifetime revenue. Peak annual product revenue for Rosiphersen alone: $500–700M.

But the real value isn't one drug. It's the platform. Every treatment we develop compresses our timelines, enriches our datasets, and proves out a repeatable model. We're building toward a future where a new ultra-rare program goes from genetic diagnosis to IND in six months — and where the platform itself becomes licensable.

AlphaRose is a Public Benefit Corporation. That's not a compromise; it's a competitive advantage. It aligns every stakeholder — patients, investors, partners — around the same outcome: treatments that work, delivered fast, at scale.

|| THE PEOPLE { 8 }

THE PEOPLE BEHIND THIS

Built by operators, not observers.

Co-Founder & CEO

Casey McPherson

Rose's father. Built To Cure A Rose Foundation, assembled the team that created Rosiphersen in under a year, and drives the company's vision, culture, and fundraising.

COO & President

Masako Nakamura

Oversees clinical development, commercialization, and pipeline operations. Leads execution of AlphaRose's path-to-market and manages new chemistry platform development, including biomarker and toxicology programs.

Chief Scientific Officer

Robert Cabrera, Ph.D.

Baylor College of Medicine. Leads all preclinical and process development activities, and oversees new technology platform development including biomarker and toxicology programs.

Head of R&D

Jeffrey Brown, Ph.D., MBA

20+ years in preclinical drug development across Pfizer, BMS, Roche, and Vertex. Leads R&D strategy and architects the multi-program portfolio that lets AlphaRose run individualized programs in parallel.

|| WHERE THIS GOES { 9 }

WHERE THIS GOES

We're not building a drug company. We're building the operating system for genetic medicine.

The endgame is a world where a child gets a genetic diagnosis and a clear conversation. Where genetic medicine is a procedure, not a decade-long development program. Where cures are manufactured at the point of care.

Every piece of this technology works today. No one has put it together.

  1. Phase 1

    Proving the platform works from design to dose.

  2. Phase 2

    Commercialization and platform expansion.

  3. Phase 3

    Platform brand expansion from design to GMP manufacturing partners.

  4. Phase 4

    Global scale — expanding to hospitals, doctors, and partners worldwide.